
Get exclusive money-saving offers and guides
Straight to your inbox
Posted
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
AdAlta Limited is a biotechnology business based in Australia. AdAlta shares (1AD) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. AdAlta has a trailing 12-month revenue of around $3.8 million..
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | $0.04 - $0.15 |
---|---|
50-day moving average | $0.1141 |
200-day moving average | $0.0916 |
Target price | N/A |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.05 |
Standard brokerage - Australian shares
Competitive broker fees on Australian and international shares
Important: Share trading carries risk of capital loss.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of A$0.125 on 2020-10-22
1 week (2021-01-15) | -13.79% |
---|---|
1 month (2020-12-23) | 4.17% |
3 months (2020-10-23) | -10.71% |
6 months (2020-07-23) | -3.85% |
1 year (2020-01-23) | 25.00% |
---|---|
2 years (2019-01-22) | -46.00% |
3 years (2018-01-23) | -52.00% |
5 years (2016-01-19) | N/A |
Revenue TTM | $3.8 million |
---|---|
Gross profit TTM | $-3,354,798 |
Return on assets TTM | -45.01% |
Return on equity TTM | -107.32% |
Profit margin | -156.92% |
Book value | 0.023 |
Market capitalisation | $33.1 million |
TTM: trailing 12 months
We're not expecting AdAlta to pay a dividend over the next 12 months.
Over the last 12 months, AdAlta's shares have ranged in value from as little as $0.04 up to $0.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while AdAlta's is 1.1844. This would suggest that AdAlta's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has a collaborative partnership with GE Healthcare to discover i-bodies against granzyme B for use as a molecular imaging agent. AdAlta Limited was incorporated in 2006 and is based in Bundoora, Australia.
Steps to owning and managing Vanguard Australian Fixed Interest Index ETF units.
Steps to owning and managing Vanguard Ethically Conscious Global Aggregate Bond Index (Hedged) ETF units.
Steps to owning and managing ETFS Morningstar Global Technology ETF units.
Steps to owning and managing BetaShares Global Quality Leaders (Currency Hedged) ETF units.
Steps to owning and managing ETFS ROBO Global Robotics and Automation ETF units.
Steps to owning and managing ETFS FANG+ ETF units.
Steps to owning and managing ETFS S&P Biotech ETF units.
Steps to owning and managing ETFS Reliance India Nifty 50 ETF units.
Steps to owning and managing BetaShares India Quality ETF units.